| 2.36 -0.15 (-5.98%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.43  |
1-year : | 5.48 |
| Resists | First : | 3.79 |
Second : | 4.69 |
| Pivot price | 2.9 |
|||
| Supports | First : | 2.32 |
Second : | 1.93 |
| MAs | MA(5) : | 2.56 |
MA(20) : | 2.94 |
| MA(100) : | 3.04 |
MA(250) : | 4.07 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 9.9 |
| RSI | RSI(14): 32.2 |
|||
| 52-week | High : | 14.1 | Low : | 2.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLRB ] has closed above bottom band by 0.5%. Bollinger Bands are 26.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.56 - 2.58 | 2.58 - 2.6 |
| Low: | 2.29 - 2.31 | 2.31 - 2.33 |
| Close: | 2.33 - 2.37 | 2.37 - 2.39 |
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Tue, 09 Jun 2026
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Fri, 05 Jun 2026
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Fri, 05 Jun 2026
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Tue, 02 Jun 2026
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named - Stock Titan
Mon, 01 Jun 2026
Iopofosine data: 16-month responses in Waldenström spur phase 3 plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 778 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -5.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103 % |
| Return on Equity (ttm) | -290.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | 3.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|